This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
Updated storage conditions for the Pfizer COVID-19 vaccine
On Monday 24 May 2021, the TGA approved an application from Pfizer Australia Pty Ltd to change its current storage conditions for its COVID-19 vaccine.
The approved storage period of the unopened thawed vial at 2-8°C (after taking out of deep-freeze conditions) has been extended from five days up to one month (31 days).
Changes to storage conditions are included in the Product Information for COMIRNATY.
As at 23 May 2021, there has been around 5.4 million doses of influenza (flu) vaccines reported to the Australian Immunisation Register (AIR).
See infographic which shows the number of flu vaccinations by patient age and immunisation provider type reported to the AIR during the 2021 flu season.
The Department of Health have also developed information brochures in a range of different languages for the 2021 influenza vaccine season.
Overcoming vaccine hesitancy
GPs and practice nurses are ideally placed to answer specific questions about people’s personal health and vaccine eligibility. A recommendation to vaccinate from a health-care professional is particularly powerful.
Reassure patients about AstraZeneca vaccine
The risk of TTS is not likely to be increased in people with the below conditions, as outlined in the ATAGI statement: Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca.
People with the following conditions can receive COVID-19 Vaccine AstraZeneca:
History of blood clots in typical sites
Increased clotting tendency that is not immune mediated
Family history of blood clots
History of ischaemic heart disease or stroke
Current or past thrombocytopenia (low platelet count)
Those receiving anticoagulation therapy
Benefits of vaccination
Vaccination against COVID-19 remains the best way to prevent severe illness and death from COVID-19.
The benefits of vaccination are many and include protection against severe illness and death from COVID-19 for the individual, as well as indirect benefits for the community.
The risk of potential outbreaks of COVID-19 is ever-present. The Australian population remains largely unimmunised and susceptible to COVID-19 risks.
If a patient doesn’t have a Medicare card, or is not eligible, refer them to get their free COVID-19 vaccination at a GP Respiratory Clinic (currently only stock AstraZeneca) or NSW state vaccination clinic (stock both Pfizer & AstraZeneca).
The Australian Technical Advisory Group on Immunisation (ATAGI) 2021 annual statement on immunisation covers key successes, trends and challenges in the use of vaccines and control of vaccine-preventable diseases in 2020. It also signals ATAGI’s priority actions for addressing key issues for 2021 and beyond.
This collection contains a suite of communication tools for General Practice-Led Respiratory Clinics (GPRC) and General Practices administering COVID-19 vaccinations.
This fact sheet provides accurate, evidence-based answers to common questions about COVID-19 vaccines. It also answers questions for multicultural communities.
This fact sheet provides information about a link between the AstraZeneca vaccine and a very rare condition, which involves blood clotting and low blood platelet levels.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
Continuing Professional Development (CPD) annual requirements Below is a snapshot of the continuing professional development (CPD) requirements for doctors, these include annual requirements of: completion of a Professional Development Plan 50 hours CPD each year, split across a range of activities: 25 hours – reviewing performance and measuring outcomes (with five hours minimum…
CESPHN’s Annual Report 2022-23 is now live Central and Eastern Sydney PHN has released its Annual Report 2022-23. The Annual Report is a summary of the key achievements and highlights for the PHN over the financial year. It is split into Improving Care Integration, Improving Practice and Commissioning Services to…